Pacira Pharma releases more data on the benefits of Exparel

|About: Pacira Pharmaceuticals, Inc. (PCRX)|By:, SA News Editor

Pacira Pharmaceuticals (PCRX) is out with results from Phase 4 studies of Exparel in laparoscopic colectomy patients.

The company says the data "reinforce findings from [the] IMPROVE trials ... demonstrating the opioid-sparing and economic benefits of Exparel."

Patients receiving the Exparel-based multimodal regimen experienced:"A 64 mg reduction in mean opioid consumption," "a 1-day reduction in median length of hospital stay," "significantly fewer opioid-related adverse events," and "a $1,784 reduction in mean hospitalization costs." (PR)